No profile data available.
111, Inc. (YI) is a healthcare company in the bulk drug suppliers industry, based in Shanghai, China, with about 1,063 full-time employees.
It reported revenue of 14.40 billion CNY for fiscal year 2024, down 3.7% from fiscal year 2023, and net income of -64.74 million CNY. In Q3 2025 (the quarter ended September 30, 2025) revenue was 3.00 billion CNY, down 16.7% from a year before. Its largest business segment, Product, brought in 50% of segment revenue in fiscal year 2025. Its market capitalization was $27.71 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B.
111 reported 14.40 billion CNY in revenue for fiscal year 2024, down 3.7% from 14.95 billion CNY in fiscal year 2023. In Q3 2025 revenue was 3.00 billion CNY.
Product, with 12.47 billion CNY or 50% of segment revenue in fiscal year 2025. Next: Drugs (46%) and Nutritional Supplements (2%).
$27.71 million as of October 9, 2026.
Listed companies of a similar size in the same industry (bulk drug suppliers) include Alfresa Holdings Corporation (ARHCF), Cosmos Health Inc. (COSM), China Medicine Corporation (CHME), Ridgetech, Inc. (RDGT).